ArticleClinical drug investigation2022

Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.

Daniel M Geynisman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.